Emergent Expects Narcan Generics To Face Uphill Struggle
Teva Launched First Generic And Sandoz An Authorized Generic In Late 2021
US rivals to Narcan will face obstacles as they attempt to compete in the public interest market, Emergent’s CEO told the virtual J.P. Morgan Healthcare Conference.
You may also be interested in...
Adamis has announced receiving FDA approval for Zimhi, its high-dose naloxone hydrochloride for injection, indicated for the treatment of opioid overdose. The company has partnered with US WorldMeds to market Zimhi by the first quarter of 2022.
Hikma has delivered on one of its key US launches for 2021 by introducing its Kloxxado naloxone 8mg nasal spray for the emergency treatment of known or suspected opioid overdose, after the 505(b)(2) product was approved by the FDA earlier this year.
Hikma expects healthy prospects for its US Advair generic in 2022, despite rival Teva recently receiving FDA approval for its own version. Meanwhile, Hikma CEO Siggi Olafsson also outlined expectations for generic competition on icosapent amid ongoing API shortages.